Multi-Omics Liquid Biopsy Innovations Transforming Solid Tumor Testing Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Solid Tumor Testing Market During 2026–2030?

The solid tumor testing market has experienced robust growth in recent years. It is projected to expand from $29.94 billion in 2025 to $32.11 billion in 2026, showing a compound annual growth rate (CAGR) of 7.3%. The growth witnessed in the past can be attributed to advancements in cancer diagnostics, the discovery of biomarkers, automation in pathology, increased oncology awareness, and various screening initiatives.

The solid tumor testing market size is predicted to undergo significant expansion in the coming years. Its value is projected to reach $43.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This forecasted growth can be attributed to the rising demand for personalized treatments, a stronger focus on early detection, the broadening scope of genomic testing, the advent of AI-driven diagnostics, and an overall increase in oncology research. Prominent trends anticipated in this period include the proliferation of liquid biopsy testing, the widespread adoption of next-generation sequencing, the growth of companion diagnostics, the incorporation of AI-based pathology, and the expansion of screening programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

Which Drivers Are Supporting The Solid Tumor Testing Market Growth?

The anticipated rise in cancer prevalence is poised to drive the expansion of the solid tumor testing market in the future. Cancer refers to a medical condition characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. Such aberrant cells, termed cancer cells, possess the ability to infiltrate adjacent tissues and organs, occasionally metastasizing to distant bodily regions via the circulatory or lymphatic systems. Approximately 90% of adult cancer diagnoses manifest as solid tumors. Solid tumor testing serves to identify cancer cells present in the bloodstream of individuals afflicted with solid tumors, even when these tumors are not yet detectable through imaging examinations. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians received a new cancer diagnosis in 2023, translating to over 450 new cases daily, with males constituting about 55% of these diagnoses. Consequently, the growing incidence of cancer is fueling the expansion of the solid tumor testing market.

How Is The Solid Tumor Testing Market Categorized Across Its Segment Groups?

The solid tumor testing market covered in this report is segmented –

1) By Type: Genetic Testing, Conventional Testing

2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

3) By Application: Clinical, Research

4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

Subsegments:

1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

Which Trends Are Expected To Impact The Solid Tumor Testing Market?

Leading companies in the solid tumor testing market are primarily focused on developing innovative solutions, such as liquid biopsy platforms for solid tumor testing. A liquid biopsy platform integrates various technologies and systems designed to analyze body fluids, predominantly blood, to identify cancer-related biomarkers. For example, in January 2023, PrognomiQ, a US-based healthcare firm, introduced its multi-omics liquid biopsy platform. PrognomiQ has since initiated the next phase of its product development by commencing a prospective clinical program with 15,000 subjects, with the first patient already enrolled. This undertaking was prompted by the potential for multi-omics markers to effectively differentiate between cancer and control cases.

Which Firms Are Influencing Competition In The Solid Tumor Testing Market?

Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

Get The Full Solid Tumor Testing Market Report:

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

Which Region Dominates The Solid Tumor Testing Market By Market Share?

North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Solid Tumor Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Solid Tumor Cancer Treatment Market Report

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

Hemato Oncology Testing Market Report

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795